Holen Sie sich die Stockscreener-App
42.96
1.81%
-0.79
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt NVO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$43.75
Offen:
$44.05
24-Stunden-Volumen:
10.66M
Relative Volume:
0.65
Marktkapitalisierung:
$190.31B
Einnahmen:
$50.91B
Nettoeinkommen (Verlust:
$18.95B
KGV:
10.08
EPS:
4.261
Netto-Cashflow:
$1.92B
1W Leistung:
-5.75%
1M Leistung:
-4.26%
6M Leistung:
-10.24%
1J Leistung:
-40.87%
1-Tages-Spanne:
$42.85
$44.22
1-Wochen-Bereich:
$41.90
$45.39
52-Wochen-Spanne:
$35.12
$81.44
Novo Nordisk Adr Stock (NVO) Company Profile
Compare NVO vs LLY, JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
42.96 | 193.81B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,131.42 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.77 | 549.25B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.23 | 397.42B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.79 | 297.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.95 | 281.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-03-18 | Eingeleitet | Bernstein | Outperform |
| 2026-03-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2026-03-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | Herabstufung | Goldman | Buy → Neutral |
| 2026-02-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2026-02-24 | Herabstufung | Kepler | Buy → Hold |
| 2026-02-23 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2026-02-12 | Hochstufung | Jefferies | Underperform → Hold |
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2025-12-08 | Herabstufung | Argus | Buy → Hold |
| 2025-10-27 | Fortgesetzt | Jefferies | Underperform |
| 2025-10-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-29 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-09-16 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-31 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-30 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Hochstufung | Kepler | Hold → Buy |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Neutral |
| 2023-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Eingeleitet | Argus | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2022-07-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-06-27 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-04-25 | Hochstufung | Cowen | Market Perform → Outperform |
| 2022-04-12 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Herabstufung | Liberum | Hold → Sell |
| 2021-12-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-07-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-05-11 | Herabstufung | UBS | Buy → Neutral |
| 2020-05-04 | Eingeleitet | Cowen | Market Perform |
| 2020-03-16 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-11-18 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-30 | Herabstufung | Jefferies | Hold → Underperform |
| 2019-06-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2017-12-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
Alle ansehen
Novo Nordisk Adr Aktie (NVO) Neueste Nachrichten
Total operating expenses of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO - TradingView
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success - The Motley Fool
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk Trial Updates Test Support For Obesity And Diabetes Valuation - Sahm
Novo Nordisk’s Adiposity Franchise Under Siege as CVS Levels the Playing Field and US Pricing Rule - AD HOC NEWS
Novo Nordisk Stock Forecast | Q1 Results and Guidance - Capital.com
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B - TradingView
US and China trade journalist expulsions in tit-for-tat moves - WPLG Local 10
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B Trade Ideas — BCBA:NVO - TradingView
Novo Nordisk A/S (ADR) stock (DK0062498333): valuation in focus after strong run for Denmark’s pha - AD HOC NEWS
NVO Stock Chart | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Discontinued operations of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO - TradingView
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B Trade Ideas — BCBA:NVOC - TradingView
Total debt per share of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO - TradingView
Revenue per share of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO - TradingView
Book value per share of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO - TradingView
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B Trade Ideas — BCBA:NVOD - TradingView
NVO News | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Total debt of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B Cash Flow – BCBA:NVOD - TradingView
Book value per share of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
Debt to equity ratio of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
Average basic shares outstanding of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
Total operating expenses of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
Net income of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock? - news.financial
Novo Nordisk Turns To OpenAI To Tighten Drug Development And Supply Chain - Sahm
NVO Stock Price, Quote & Chart | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Novo Nordisk A/S ADR (NVO-N) Stock Price and News - The Globe and Mail
Novo Nordisk stock (DK0062498333): Wegovy growth and U.S. demand stay in focus - AD HOC NEWS
Novo Nordisk A/ S stock (DK0060534915): weight-loss boom meets fresh earnings update - AD HOC NEWS
NVO Technical Analysis | Trend, Signals & Chart Patterns | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Novo Nordisk A/S stock (DK0062498333): weight-loss demand drives fresh guidance upgrade - AD HOC NEWS
Novo Nordisk A/S stock (DK0062498333): Wegovy data and earnings outlook keep GLP-1 race in focus - AD HOC NEWS
Novo Nordisk Highlights New Wegovy Pill Data - Sahm
Novo Nordisk A/ S stock (DK0060534915): Up 1.29% to $47 amid recovery trend - AD HOC NEWS
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Finanzdaten der Novo Nordisk Adr-Aktie (NVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.15%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):